Ventrus Biosciences

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Ventrus Biosciences ( VTUS) is a specialty pharmaceutical company focused on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. This stock is trading up 5.3% to $4.01 in recent trading.

Today's Range: $3.77-$4.04

52-Week Range: $3.46-$13.53

Volume: 72,000

Three-Month Average Volume: 303,604

Shares of VTUS are moving sharply higher today in front of its upcoming presentation at the Stifel Nicolaus 2012 Healthcare Conference today and at the UBS Global Life Sciences Conference on Sept. 20.

>>5 Stocks Set to Soar on Bullish Earnings From a technical perspective, VTUS is starting to move back above its 50-day moving average of $3.85 here with light volume. This move is coming after VTUS gapped down huge in June from over $12 to below $5 with monster volume. Following that plunge, shares of VTUS went on to hit a low of $3.46, and then trended sideways between $3.55 and $4.14 for two months. Shares of VTUS are now quickly moving into range of triggering a near-term breakout trade. That trade will hit once VTUS clears some near-term overhead resistance at $4.15 to $4.40 with high volume.

Traders should now look for long-biased trades in VTUS as long as its trending above its 50-day, and then once it sustains a move or close above $4.15 to $4.40 with volume that's near or above 303,604 shares. If that breakout triggers soon, then VTUS will have a great chance of hitting $5 to $6 in the near future.

If you liked this article you might like

'Cloud Wars' Intensify; Staples Shows Some Staying Power -- ICYMI Friday

North Korea Threat Pulls Wall Street Lower

Geopolitical Risk Is So Hot, Investors Get Primed for the Ultimate Fire Sale: Market Recon

North Korea, Disney and Netflix - 5 Things You Must Know Before the Market Opens